Floatz logo

Durvalumab

Gall Bladder Cancer

Lisata Therapeutics, Inc.monoclonal_antibodyPhase 2Active
B
60/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
45/ 100
Competitive Position
89/ 100

Competitive context

15 Active assets in the Gall Bladder Cancer cohort.

Asset / SponsorPhaseRating
Eloxatin
Tianjin Medical University Cancer Institute and Hospital
Phase 3BB
Irinotecan
Merck Sharp & Dohme LLC
Phase 2BB
Docetaxel
Merck Sharp & Dohme LLC
Phase 2BB
Cyclophosphamide
Merck Sharp & Dohme LLC
Phase 2BB
Epirubicin
Merck Sharp & Dohme LLC
Phase 2BB

View all 21 →

Same molecule, other indications

Durvalumab is also rated in:

primary peritoneal carcinomaDormant
BB
Indicative ·
70 / 100
View asset →
ovarian carcinomaDormant
BB
Indicative ·
70 / 100
View asset →
urothelial carcinomaDormant
BB
Indicative ·
70 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →